Publikationen von 0000-0002-1125-4060
(ORCID: 0000-0002-1125-4060)
![]() | Eine Stufe nach oben |
Anzahl der Einträge: 2.
Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu
, Hogan, William J.
, Etra, Aaron, Choe, Hannah, Hexner, Elizabeth
, Langston, Amelia
, Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. und Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), S. 5189-5198.
Volltext nicht vorhanden.
, Hogan, William J.
, Etra, Aaron, Choe, Hannah, Hexner, Elizabeth
, Langston, Amelia
, Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. und Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), S. 5189-5198.
Volltext nicht vorhanden.
Srinagesh, Hrishikesh K., Özbek, Umut, Kapoor, Urvi, Ayuk, Francis, Aziz, Mina, Ben-David, Kaitlyn, Choe, Hannah K., DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan A., Hartwell, Matthew J.
, Hexner, Elizabeth O.
, Hogan, William J., Karol, Alexander B., Kasikis, Stelios, Kitko, Carrie L., Kowalyk, Steven, Lin, Jung-Yi, Major-Monfried, Hannah, Mielke, Stephan, Merli, Pietro, Morales, George, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reddy, Pavan, Reshef, Ran, Rösler, Wolf, Sandhu, Karamjeet S., Schechter, Tal, Shah, Jay, Sigel, Keith, Weber, Daniela, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Levine, John E. und Ferrara, James L. M.
(2019)
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.
Blood Advances 3 (23), S. 4034-4042.
Volltext nicht vorhanden.
, Hexner, Elizabeth O.
, Hogan, William J., Karol, Alexander B., Kasikis, Stelios, Kitko, Carrie L., Kowalyk, Steven, Lin, Jung-Yi, Major-Monfried, Hannah, Mielke, Stephan, Merli, Pietro, Morales, George, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reddy, Pavan, Reshef, Ran, Rösler, Wolf, Sandhu, Karamjeet S., Schechter, Tal, Shah, Jay, Sigel, Keith, Weber, Daniela, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Levine, John E. und Ferrara, James L. M.
(2019)
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.
Blood Advances 3 (23), S. 4034-4042.
Volltext nicht vorhanden.
